Table 2 System response of sofosbuvir, velpatasvir, ledipasvir, and daclatasvir in complete composite design
S.No | Combination | % organic phase | pH | Flow rate | Theoretical (sofosbuvir) | Theoretical (velpatasvir) | Theoretical (ledipasvir) | Theoretical (daclatasvir) |
|---|---|---|---|---|---|---|---|---|
X1 | X2 | X3 | ||||||
1 | 1 | 30 | 4.0 | 0.6 | 17,398.754 | 921 | 955 | 934 |
2 | X1 | 70 | 4.0 | 0.6 | 2845.40 | 7132.22 | 4852.92 | 1506.5 |
3 | X2 | 30 | 6.0 | 0.6 | 19,215.652 | 932 | 965 | 956 |
4 | X1X2 | 70 | 6.0 | 0.6 | 8357.634 | 8403.91 | 5528.55 | 7649.63 |
5 | X3 | 30 | 4.0 | 1.0 | 12,942.93 | 984 | 964.5 | 990 |
6 | X1X3 | 70 | 4.0 | 1.0 | 2841.49 | 5047.30 | 3683.29 | 4144.34 |
7 | X2X3 | 30 | 6.0 | 1.0 | 15,081.284 | 989 | 978 | 949 |
8 | X1X2X3 | 70 | 6.0 | 1.0 | 5090.77 | 5660.94 | 3738.79 | 4541.39 |